Reducing Asymptomatic Infection With Vitamin D in Coronavirus Disease
Status:
Not yet recruiting
Trial end date:
2021-04-28
Target enrollment:
Participant gender:
Summary
This study is intended to address whether oral daily vitamin D supplementation reduces
infection with SARS-CoV-2 in healthy young adults.
The primary aim of the study is to demonstrate a reduction in 'silent' seroconversion rates,
consistent with asymptomatic transmission of SARS-CoV-2, in a young healthy adult population
following 24 weeks of taking oral vitamin D supplemented at a dose of 1000 I.U. daily, versus
matching placebo.
The secondary aims of this study are to explore:
1. Any effect on symptomatic illness.
2. The background 'point' prevalence and subsequent rate of increase in seropositivity for
SARS-CoV-2 in healthy young adults.
3. The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in
seropositivity in a defined young adult population over time.
4. Where salivary Immunoglobulin A (IgA) may be used to provide an alternative/
complementary serological method
5. The effect (if any) of vitamin D supplementation on seroconversion rates stratified by:
i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' status; ii)
extent of BMI-defined normal/overweight/obesity cut-offs and iii) gender.